Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole.

Abstract

BACKGROUND:

Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on the long-term maintenance of healing of EE are available, but data on long-term GERD symptom prevention and patient quality of life (QOL) are limited.

AIMS:

To investigate QOL in subjects with healed EE who received 12 months of double-blind maintenance treatment with lansoprazole or ranitidine, followed by long-term open-label lansoprazole therapy to prevent recurrence of EE.

METHODS:

Subjects with healed EE received 12 months of double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily, followed by dose-titrated, open-label lansoprazole therapy for up to 82 months.

RESULTS:

During double-blind treatment (n = 206), lansoprazole-treated patients showed significantly (P <or= 0.05) greater improvements than ranitidine-treated patients in the frequency, severity, and 'bothersomeness' of heartburn, the symptom index, problems of activity limitation, eating and drinking problems, symptom problems, health distress, and social functioning. During dose-titrated, open-label treatment (n = 195), all disease-specific QOL scales except sleep improved significantly (P < 0.001) from open-label baseline at each time-point.

CONCLUSIONS:

Maintenance treatment with lansoprazole for 12 months in healed EE subjects produced significantly greater improvements in QOL indicators than ranitidine. These improvements were sustained during dose-titrated, open-label lansoprazole treatment.

• Authors: Thomas O Kovacs, James W Freston, Marian M Haber, Stuart Atkinson, Barbara Hunt, David A Peura
• Journal: Digestive diseases and sciences (Dig Dis Sci) Vol. 55 Issue 5 Pg. 1325-36 (May 2010) ISSN: 1573-2568 [Electronic] United States
• PMID: 19582579 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents
• Lansoprazole
• Ranitidine

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (administration & dosage, therapeutic use)
• Adult
• Aged
• Aged, 80 and over
• Analysis of Variance
• Anti-Ulcer Agents (administration & dosage, therapeutic use)
• Double-Blind Method
• Esophagitis (drug therapy)
• Female
• Humans
• Lansoprazole
• Male
• Middle Aged
• Quality of Life
• Ranitidine (administration & dosage, therapeutic use)
• Surveys and Questionnaires
• Treatment Outcome